Rare and childhood cancer multi-omics for precision medicine

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211015001

Enrollment

1000

Registered

2021-10-15

Start date

2022-01-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk neuroblastoma, refractory or relapsed Osteosarcoma Non-rhabdosarcoma solid tumors Brain tumors: embryonal tumors &amp

Interventions

patients who are under 18 years of age with diagnosed high-risk, refractory, or relapsed diseases of pediatric neuroblastoma, osteosarcoma, brain tumors (including embryonal germline tumors and glioma

Diagnostic

rare pediatric cancer

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Age less than 18 years with High-risk neuroblastoma, refractory or relapsed or Osteosarcoma or Non-rhabdosarcoma solid tumors or Brain tumors: embryonal tumors & diffused/high grade gliomas or Atypical teratoid/rhabdoid tumor

Exclusion criteria

Exclusion criteria: 1. No biological parents available 2. Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Cancer predisposing gene 1 month Not statistical method	—

Secondary

Measure	Time frame
Novel targeted therapy 6 months Not statistical method	—

Countries

Thailand

Contacts

Public ContactUsanarat Anurathapan

Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University

usanarat.anu@mahidol.ac.th0642345626

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026